bioAffinity Technologies, Inc. develops and commercializes noninvasive diagnostics for lung cancer and other lung diseases. The company’s first product, CyPath® Lung, is a sputum-based Laboratory Developed Test marketed by Precision Pathology Laboratory Services, a bioAffinity subsidiary, and uses flow cytometry with automated AI-informed analysis to identify cell populations associated with lung malignancy.
Recurring company news centers on CyPath® Lung commercialization, physician adoption, clinical case studies, pulmonary nodule management, lung cancer risk assessment, and post-treatment surveillance. Updates also cover financial results, laboratory-services focus, medical conference and physician-education activity, and research extending the company’s flow cytometry+AI platform toward asthma and COPD diagnostics.
bioAffinity Technologies (Nasdaq: BIAF) priced a public offering for approximately $3.2 million in gross proceeds. The deal includes 4,000,000 common shares, or pre-funded warrants in lieu, at $0.80 per share or $0.793 per pre-funded warrant.
The offering is made under effective Form S-1 (File No. 333-296764) and is expected to close on or about June 18, 2026, subject to customary conditions. WallachBeth Capital serves as sole placement agent.
bioAffinity Technologies (Nasdaq:BIAF) announced a July 21, 2026 webinar focused on advancing veteran lung health. Clinical experts from Philips, bioAffinity Technologies and 4DMedical will discuss mobile CT screening, noninvasive CyPath® Lung testing, and functional lung imaging for earlier detection and improved management of respiratory disease in U.S. veterans.
bioAffinity Technologies (Nasdaq:BIAF) announced that the Society for Advanced Bronchoscopy will host a webinar on the noninvasive CyPath® Lung test and its role in managing early-stage lung cancer.
The June 16, 7 p.m. ET session will feature a multidisciplinary physician panel sharing real-world clinical use cases.
bioAffinity Technologies (Nasdaq:BIAF) announced notification of allowance from the Mexican Institute of Industrial Property for a patent covering CyPath® Lung methods that predict lung cancer likelihood using flow cytometry.
The patent will protect use of specific antibodies, TCPP porphyrin labeling, and flow cytometry on sputum samples, expanding CyPath® Lung’s intellectual property portfolio that already includes patents in the United States, European Union, China, Japan, Australia, Canada and Mexico.
CyPath® Lung is a commercially available, noninvasive test that combines advanced cell biology, flow cytometry, artificial intelligence and at-home sample collection to help clinicians assess indeterminate pulmonary nodules in high-risk patients, support treatment decisions and potentially reduce healthcare costs.
bioAffinity Technologies (Nasdaq:BIAF) reported record monthly unit sales for its CyPath® Lung diagnostic test in April 2026, with units up nearly 300% versus April 2025 based on preliminary unaudited data.
The company highlights accelerating physician adoption, integration into clinical workflows, and new studies and R&D to expand applications.
bioAffinity Technologies (Nasdaq: BIAF) reported Q1 2026 results and growing adoption of CyPath® Lung. Unit sales rose 146% YoY; CyPath testing revenue was $361,000 (≈114% increase). Total revenue was $1.4M (down ~27%). Q1 net loss was $3.6M or $(0.81) per share. Cash and cash equivalents were $3.1M as of March 31, 2026. The company launched a large longitudinal trial (up to 20 sites) partially funded by the U.S. Department of Defense and reported a 40-patient collaborative study at Brooke Army Medical Center.
bioAffinity Technologies (Nasdaq: BIAF) launched a pilot study with Brooke Army Medical Center to evaluate its flow cytometry+AI tests for identifying inflammatory biomarkers in asthma and COPD. The study will enroll ~40 participants across asthma, COPD and healthy-control cohorts to assess sputum immune cells and cytokines.
The collaboration aims to support precision diagnostics and treatment monitoring for airway diseases and references a potential asthma/COPD treatment market estimated at $92 billion.
bioAffinity Technologies (NASDAQ: BIAF) published a clinical case study showing its noninvasive sputum test CyPath® Lung supported physician judgment, prompted follow-up imaging and helped defer an unnecessary lung biopsy for a high‑risk 70‑year‑old patient on April 14, 2026.
The company reports the test showed 92% sensitivity, 87% specificity and 88% accuracy in a clinical trial of difficult-to-diagnose small nodules; the patient’s initial 30 mm nodule fully resolved on repeat CT after a negative CyPath result, avoiding a risky invasive procedure.
bioAffinity Technologies (Nasdaq: BIAF) will feature its CyPath® Lung test at the Cleveland Clinic "Advances in Early Lung Cancer Detection" symposium on April 16, 2026. Chief Medical Officer Gordon Downie, MD, PhD, will join a panel on lung nodule management to discuss CyPath® Lung's role in early detection.
The invitation-only event focuses on risk assessment, screening biomarkers, AI, and emerging diagnostics to find lung cancer at its most treatable stages.
bioAffinity Technologies (Nasdaq: BIAF) reported that CyPath Lung unit sales in Q1 2026 rose 146% year-over-year on preliminary unaudited data, reflecting accelerating physician adoption. The company noted 2025 revenue +87% YoY and test units +99% vs 2024, targeting a $3.58B U.S. addressable market.
Management highlighted clinical use in nodule management, a planned large longitudinal study, and R&D into asthma and COPD diagnostics to broaden the platform.